What is Creyon Bio?
Creyon Bio operates at the intersection of advanced computational biology and precision medicine. By reimagining drug development through a data-centric lens, the company generates uniquely powerful datasets that inform its machine learning models. These models are designed to uncover the fundamental engineering principles required to develop oligonucleotide-based medicines. By focusing on these molecular building blocks, Creyon Bio aims to address patient populations of all sizes, effectively bridging the gap between complex biological data and scalable, high-efficacy therapeutic solutions. Its market position is defined by its ability to transform the traditionally slow and costly drug discovery process into a streamlined, data-driven engineering discipline.
How much funding has Creyon Bio raised?
Creyon Bio has raised a total of $40M across 1 funding round:
Series A
$40M
Series A (2022): $40M with participation from DCVC Management, BioBrit, Lux Capital, Alexandria, and Casdin Capital
Key Investors in Creyon Bio
DCVC Management
DCVC is a deep tech venture capital firm that invests in entrepreneurs tackling some of the world's most challenging problems, with a specific focus on leveraging artificial intelligence to unlock potential in biotechnology.
Lux Capital
Lux Capital is a venture capital firm that invests in early-stage and growth-stage companies at the intersection of science and technology, backing founders in frontier areas such as biotechnology and advanced materials.
Casdin Capital
Casdin Capital brings a deep understanding and long-term perspective to financing the next generation of life science innovation, with a strong track record in diagnostics and molecular information.
What's next for Creyon Bio?
With this major strategic investment, Creyon Bio is poised to scale its pre-clinical operations and further refine its machine learning infrastructure. The capital will likely be deployed to expand the company's internal research capabilities and strengthen its pipeline of oligonucleotide candidates. As the firm transitions into its next phase of growth, the focus will remain on validating its computational models against clinical outcomes, thereby solidifying its role as a leader in the next generation of precision therapeutics. The backing from top-tier venture firms provides not only the necessary financial runway but also the strategic guidance required to navigate the complex regulatory and scientific hurdles inherent in the biotechnology sector.
See full Creyon Bio company page
